Share Price and Basic Stock Data
Last Updated: December 9, 2024, 10:16 pm
PEG Ratio | 16.38 |
---|
Competitors of Sanofi India Ltd
Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
---|---|---|---|---|---|---|---|---|---|
Gujarat Themis Biosyn Ltd | 3,608 Cr. | 331 | 390/108 | 68.5 | 20.5 | 0.20 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 60.2 Cr. | 81.2 | 94.9/26.6 | 23.1 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
Gujarat Inject (Kerala) Ltd | 27.8 Cr. | 19.0 | 19.5/8.35 | 36.1 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
Godavari Drugs Ltd | 95.5 Cr. | 127 | 155/87.0 | 14.3 | 55.4 | 0.00 % | 12.7 % | 15.5 % | 10.0 |
Glenmark Life Sciences Ltd | 12,639 Cr. | 1,030 | 1,335/627 | 29.8 | 207 | 2.18 % | 28.1 % | 21.1 % | 2.00 |
Industry Average | 19,709.05 Cr | 1,260.26 | 58.76 | 184.91 | 0.31% | 16.36% | 16.88% | 6.61 |
Quarterly Result
Month | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 789 | 754 | 688 | 707 | 699 | 692 | 672 | 736 | 515 | 715 | 694 | 511 | 464 |
Expenses | 542 | 556 | 561 | 512 | 538 | 510 | 505 | 507 | 393 | 506 | 506 | 374 | 348 |
Operating Profit | 247 | 199 | 127 | 194 | 161 | 182 | 167 | 230 | 122 | 208 | 187 | 137 | 116 |
OPM % | 31% | 26% | 18% | 28% | 23% | 26% | 25% | 31% | 24% | 29% | 27% | 27% | 25% |
Other Income | 17 | 504 | 16 | 142 | 16 | 11 | 34 | 44 | 57 | 12 | 12 | 41 | 21 |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Depreciation | 21 | 14 | 11 | 11 | 11 | 10 | 10 | 10 | 9 | 10 | 10 | 9 | 9 |
Profit before tax | 243 | 688 | 132 | 326 | 166 | 182 | 190 | 264 | 169 | 210 | 189 | 169 | 127 |
Tax % | 26% | 23% | 32% | 27% | 27% | 28% | 31% | 28% | 27% | 28% | 27% | 19% | 19% |
Net Profit | 178 | 530 | 90 | 238 | 120 | 131 | 131 | 190 | 123 | 152 | 138 | 137 | 103 |
EPS in Rs | 77.52 | 230.35 | 39.30 | 103.65 | 52.35 | 56.91 | 56.91 | 82.78 | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 |
Last Updated: October 25, 2024, 4:12 pm
Profit & Loss - Annual Report
Last Updated: October 25, 2024, 4:12 pm
Month | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 1,573 | 1,809 | 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 2,851 | 2,383 |
Expenses | 1,261 | 1,411 | 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 2,047 | 1,734 |
Operating Profit | 312 | 398 | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 804 | 649 |
OPM % | 20% | 22% | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 28% | 27% |
Other Income | 41 | 83 | 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 83 | 86 |
Interest | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 1 |
Depreciation | 90 | 92 | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 40 | 38 |
Profit before tax | 262 | 388 | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 846 | 695 |
Tax % | 32% | 32% | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 29% | |
Net Profit | 177 | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 530 |
EPS in Rs | 76.81 | 115.30 | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.26 | 230.39 |
Dividend Payout % | 43% | 39% | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% |
YoY Net Profit Growth
Year |
---|
YoY Net Profit Growth (%) |
Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 1% |
3 Years: | -1% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 9% |
3 Years: | 5% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 8% |
3 Years: | 10% |
1 Year: | 26% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 27% |
3 Years: | 33% |
Last Year: | 52% |
Last Updated: Unknown
Balance Sheet
Last Updated: Unknown
Month | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Jun 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
Reserves | 1,181 | 1,324 | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 662 |
Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 22 |
Other Liabilities | 427 | 532 | 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 654 |
Total Liabilities | 1,631 | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,360 |
Fixed Assets | 699 | 699 | 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 302 |
CWIP | 43 | 136 | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 29 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
Other Assets | 888 | 1,043 | 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,382 | 1,029 |
Total Assets | 1,631 | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,360 |
Cash Flow
Month | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | 312.00 | 398.00 | 339.00 | 376.00 | 535.00 | 538.00 | 625.00 | 667.00 | 693.00 | 737.00 | 680.00 | 785.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 23 | 24 | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 17 |
Inventory Days | 135 | 151 | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 202 |
Days Payable | 75 | 83 | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 89 |
Cash Conversion Cycle | 83 | 92 | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 130 |
Working Capital Days | 3 | 43 | 26 | 9 | 79 | 17 | 18 | 35 | -7 | -19 | -18 | 25 |
ROCE % | 23% | 29% | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 71% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
Aditya Birla Sun Life Frontline Equity Fund | 268,508 | 0.84 | 216.62 | 100,837 | 2024-12-09 | 166.28% |
Nippon India Pharma Fund | 236,008 | 2.94 | 190.4 | 100,837 | 2024-12-09 | 134.05% |
Nippon India Growth Fund | 226,766 | 0.78 | 182.94 | 100,837 | 2024-12-09 | 124.88% |
Nippon India Small Cap Fund | 196,342 | 0.36 | 158.4 | 100,837 | 2024-12-09 | 94.71% |
SBI Contra Fund | 161,000 | 0.68 | 129.5 | 100,837 | 2024-12-09 | 59.66% |
Nippon India Multi Cap Fund | 152,371 | 0.5 | 122.93 | 100,837 | 2024-12-09 | 51.11% |
SBI Long Term Equity Fund | 147,988 | 0.69 | 119.04 | 100,837 | 2024-12-09 | 46.76% |
Aditya Birla Sun Life Small Cap Fund | 144,433 | 2.22 | 116.52 | 100,837 | 2024-12-09 | 43.23% |
SBI Magnum Midcap Fund | 100,837 | 0.56 | 81.11 | 100,837 | 2024-12-09 | 0% |
Aditya Birla Sun Life Multi-Cap Fund | 87,342 | 1.43 | 70.46 | 100,837 | 2024-12-09 | -13.38% |
Key Financial Ratios
Month | Dec 23 |
---|---|
FaceValue | 10.00 |
Basic EPS (Rs.) | 261.78 |
Diluted EPS (Rs.) | 261.78 |
Cash EPS (Rs.) | 279.35 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 441.39 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 441.39 |
Revenue From Operations / Share (Rs.) | 1239.61 |
PBDIT / Share (Rs.) | 377.83 |
PBIT / Share (Rs.) | 360.61 |
PBT / Share (Rs.) | 367.61 |
Net Profit / Share (Rs.) | 262.13 |
NP After MI And SOA / Share (Rs.) | 262.13 |
PBDIT Margin (%) | 30.47 |
PBIT Margin (%) | 29.09 |
PBT Margin (%) | 29.65 |
Net Profit Margin (%) | 21.14 |
NP After MI And SOA Margin (%) | 21.14 |
Return on Networth / Equity (%) | 59.38 |
Return on Capital Employeed (%) | 77.98 |
Return On Assets (%) | 35.15 |
Current Ratio (X) | 1.92 |
Quick Ratio (X) | 0.89 |
Dividend Payout Ratio (NP) (%) | 139.85 |
Dividend Payout Ratio (CP) (%) | 131.23 |
Earning Retention Ratio (%) | -39.85 |
Cash Earning Retention Ratio (%) | -31.23 |
Interest Coverage Ratio (X) | 511.18 |
Interest Coverage Ratio (Post Tax) (X) | 345.18 |
Enterprise Value (Cr.) | 18147.83 |
EV / Net Operating Revenue (X) | 6.37 |
EV / EBITDA (X) | 20.88 |
MarketCap / Net Operating Revenue (X) | 6.51 |
Retention Ratios (%) | -39.85 |
Price / BV (X) | 18.28 |
Price / Net Operating Revenue (X) | 6.51 |
EarningsYield | 0.03 |
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
- Net Profit Margin: 21.14%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 77.98% (Industry Average ROCE: 16.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 59.38% (Industry Average ROE: 16.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 345.18
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.4 (Industry average Stock P/E: 47.44)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 21.14%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | Sanofi House, Mumbai Maharashtra 400072 | igrc.sil@sanofi.com http://www.sanofiindialtd.com |
Management | |
---|---|
Name | Position Held |
Mr. Aditya Narayan | Chairman & Ind.Director |
Mr. Rodolfo Hrosz | Managing Director |
Mr. Rachid Ayari | WholeTime Director & CFO |
Ms. Renee Amonkar | Whole Time Director |
Mr. Vaibhav Karandikar | Non Executive Director |
Mrs. Usha Thorat | Independent Director |
Mr. Rahul Bhatnagar | Independent Director |
FAQ
What is the latest intrinsic value of Sanofi India Ltd?
The latest intrinsic value of Sanofi India Ltd as on 10 December 2024 is ₹5419.27, which is 14.01% lower than the current market price of ₹6,302.00. The stock has a market capitalization of 14,523 Cr. and recorded a high/low of ₹7,600/4,606 during the current fiscal year 2024-2025. As of Jun 2024, the company has reserves of ₹662 Cr and total liabilities of ₹1,360 Cr.
What is the Market Cap of Sanofi India Ltd?
The Market Cap of Sanofi India Ltd is 14,523 Cr..
What is the current Stock Price of Sanofi India Ltd as on 10 December 2024?
The current stock price of Sanofi India Ltd as on 10 December 2024 is 6,302.
What is the High / Low of Sanofi India Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Sanofi India Ltd stocks is 7,600/4,606.
What is the Stock P/E of Sanofi India Ltd?
The Stock P/E of Sanofi India Ltd is 34.4.
What is the Book Value of Sanofi India Ltd?
The Book Value of Sanofi India Ltd is 298.
What is the Dividend Yield of Sanofi India Ltd?
The Dividend Yield of Sanofi India Ltd is 2.65 %.
What is the ROCE of Sanofi India Ltd?
The ROCE of Sanofi India Ltd is 71.1 %.
What is the ROE of Sanofi India Ltd?
The ROE of Sanofi India Ltd is 51.5 %.
What is the Face Value of Sanofi India Ltd?
The Face Value of Sanofi India Ltd is 10.0.